Secondary Faculty

An asterisk (*) denotes faculty who participate in the Anti-Cancer Drug Development Training Program.

*Richard F. Ambinder, M.D., Ph.D., Professor
Virology and human cancer; antiviral therapy; antitumor therapy; lymphoma pathogenesis and treatment; immunological approaches to virus-associated malignancies.

Namandje N. Bumpus, Ph.D., Assistant Professor
Role of drug metabolism in non-nucleoside reverse transcriptase inhibitor-mediated toxicity.

*Samuel R. Denmeade, M.D., Professor
Targeted therapies for cancer; prodrugs; proteases; peptide libraries.

*Phillip A. Dennis, M.D., Ph.D., Professor

Kelly E. Dooley, M.D., Ph.D., Assistant Professor
Clinical pharmacology of anti-infective agents; Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV.

Charles W. Flexner, M.D., Professor
Basic and clinical pharmacology of antiretroviral drugs; HIV protease inhibitors and entry inhibitors.

*Robert H. Getzenberg, Ph.D., Professor
Cancer biomarkers; proteomic analysis of nuclear structure; nanotechnology.

*Gary S. Hayward, Ph.D., Professor
Pathways of herpesvirus gene regulation and latency; cis-acting DNA elements that modulate gene expression; mechanisms of positive and negative transcriptional regulation; interaction of viral immediate-early transactivators with nuclear domains; molecular piracy by Kaposi's sarcoma herpesvirus.

*S. Diane Hayward, Ph.D., Professor
Epstein-Barr virus and Kaposi's sarcoma virus; viral latency and tumorigenesis; mechanisms of virus-induced cell proliferation; viral mediated epigenetic modification of cell gene expression; notch and wnt pathways.

Craig W. Hendrix, M.D., Professor
Anti-infective drugs; chemoprevention of infectious diseases.

Walter C. Hubbard, Ph.D., Associate Professor
Quantitative mass spectrometry via combined liquid chromatography-tandem mass spectrometry and applications to clinical and laboratory research; (1) pharmacokinetics and metabolism of agents employed for treatment of HIV/AIDS and other viral disease; (2) lipid molecular species: potential for newborn screening for leukodystrophies and roles as mediators of signal transduction in cells.

Takanari Inoue, Ph.D., Assistant Professor
Synthetic cell biology, neutrophil chemotaxis, spatio-temporal signal compartmentalization, confocal fluorescence imaging, technology development.

*Daniel J. Leahy, Ph.D., Professor 
Molecular studies of signal transduction.

*William G. Nelson, M.D., Ph.D., Professor
Molecular mechanisms of prostatic carcinogenesis; epigenetic alterations in cancer; new approaches to prostate cancer prevention and treatment.

Duojia Pan, Ph.D., Professor
Growth control in normal development and cancer; signal transduction; animal models of cancer.

Brent Petty, M.D., Associate Professor
Antimicrobial chemotherapy; hospital-based medical practices; internal medicine collaboration with ophthalmologic clinical trials.

*Martin G. Pomper, M.D., Ph.D., Professor
In Vivo molecular and cellular imaging; radiopharmaceutical development; targeted cancer imaging and therapy; functional brain imaging.

*Jonathan D. Powell, M.D., Ph.D., Associate Professor
Mechanisms of T cell activation and tolerance.

*Douglas N. Robinson, Ph.D., Associate Professor
Understanding cytokinesis and cell shape control.

Christopher A. Ross, M.D., Ph.D., Professor
Neuropsychiatric disorders.

Theresa A. Shapiro, M.D., Ph.D., Professor
Clinical pharmacology; molecular mechanisms of antiparasitic drug action; effects of topoisomerase inhibitors on DNA of trypanosomes; structure-activity of synthetic antimalarial trioxanes.

Robert F. Siliciano, M.D., Ph.D., Professor
HIV latency, evolution, and persistence; HIV treatment and drug resistance; pharmacology of HIV drugs.

Solomon H. Snyder, M.D., Professor
Molecular basis of neural signal transduction.